Research programme: liposomal nucleic acid therapeutics - Bio-Path Holdings

Drug Profile

Research programme: liposomal nucleic acid therapeutics - Bio-Path Holdings

Alternative Names: BP-100-1.02; BP-100-2.01; BP-1002; BP-1003; Liposomal Bcl-2; Liposomal Bcl2 antisense

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Bio-Path Holdings
  • Class Antisense RNA; Small interfering RNA
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Follicular lymphoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 07 Nov 2017 Preclinical development is ongoing in USA
  • 06 Nov 2017 Preclinical trials in Pancreatic cancer in USA (IV)
  • 06 Nov 2017 Bio-Path announces intention to submit IND to US FDA for Pancreatic cancer in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top